Environmental contaminants perturb fragile protein assemblies and inhibit normal protein function

Current Chemical Biology

Volumn 7, Issue 2, 2013, Pages 196-206

  Lawrence, Sarah H ^a   Selwood, Trevor ^a   Jaffe, Eileen K ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ALAD; ALAD porphyria; Environmental contaminants; Enzyme inhibition; Lead poisoning; Morpheein; PBGS; Protein assembly

Indexed keywords

2 CHLOROBENZALDEHYDE; 2 NITROBENZYL CHLORIDE; 2,4 DICHLOROBENZALDEHYDE; 2,6 DICHLOROBENZALDEHYDE; 3 BROMOBENZALDEHYDE; 3,4 DICHLOROBENZALDEHYDE; CADMIUM ACETATE; CADMIUM CHLORIDE; CAPTAN; CISPLATIN; METHYL 4 FORMYL BENZOATE; MUTAGENIC AGENT; N METHYL 4 AMINOPHENOL SULFATE; NITROFURAL; NITROFURANTOIN; PORPHOBILINOGEN SYNTHASE; RESORCINOL DIGLYCIDYL ETHER; UNCLASSIFIED DRUG; VALERENIC ACID;

ARTICLE; CATALYSIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LEAD POISONING; OCCUPATIONAL EXPOSURE; POLLUTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PORPHYRIA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84876718671     PISSN: 22127968     EISSN: 18723136     Source Type: Journal    
DOI: 10.2174/2212796811307020011     Document Type: Article

References (54)

1. Lamon, J.M.; Frykholm, B.C.; Tschudy, D.P., Tyrosinemia with aminolevulinic dehydratase deficiency. J Pediatr, 1978, 92, (2), 346.
2. Maruno, M.; Furuyama, K.; Akagi, R.; Horie, Y.; Meguro, K.; Garbaczewski, L.; Chiorazzi, N.; Doss, M.O.; Hassoun, A.; Mercelis, R.; Verstraeten, L.; Harper, P.; Floderus, Y.; Thunell, S.; Sassa, S., Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood, 2001, 97, (10), 2972-2978.
3. Mitchell, G.; Larochelle, J.; Lambert, M.; Michaud, J.; Grenier, A.; Ogier, H.; Gauthier, M.; Lacroix, J.; Vanasse, M.; Larbrisseau, A.; et al., Neurologic crises in hereditary tyrosinemia. N Engl J Med, 1990, 322, (7), 432-437.
4. Pietrangelo, A., The porphyrias: pathophysiology. Intern Emerg Med, 2010, 5 Suppl 1, S65-71.
5. Warren, M.J.; Cooper, J.B.; Wood, S.P.; Shoolingin-Jordan, P.M., Lead poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. Trends Biochem Sci, 1998, 23, (6), 217-221.
6. Jaffe, E.K.; Martins, J.; Li, J.; Kervinen, J.; Dunbrack, R.L., The molecular mechanism of lead inhibition of human porphobilinogen synthase. J Biol Chem, 2001, 276, (2), 1531-1537.
7. Adhikari, A.; Penatti, C.A.; Resende, R.R.; Ulrich, H.; Britto, L.R.; Bechara, E.J., 5-Aminolevulinate and 4, 5-dioxovalerate ions decrease GABA(A) receptor density in neuronal cells, synaptosomes and rat brain. Brain Res, 2006, 1093, (1), 95-104.
8. Reiter, R.J.; Manchester, L.C.; Tan, D.X., Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol, 2010, 8, (3), 194-210.
9. Taljaard, J.J.; Lamm, M.C.; Truter, L.; McCarthy, B.W.; Percy, V.A.; Neethling, A.C., [Mechanism of delta-aminolevulinic acid neurotoxicity]. S Afr Med J, 1981, 60, (5), 180-183.
10. Jaffe, E.K.; Lawrence, S.H., The morpheein model of allostery: evaluating proteins as potential morpheeins. Methods Mol Biol, 2012, 796, 217-231.
11. Selwood, T.; Tang, L.; Lawrence, S.H.; Anokhina, Y.; Jaffe, E.K., Kinetics and thermodynamics of the interchange of the morpheein forms of human porphobilinogen synthase. Biochemistry, 2008, 47, (10), 3245-3257.
12. Jaffe, E.K.; Stith, L., ALAD porphyria is a conformational disease. Am J Hum Genet, 2007, 80, (2), 329-337.
13. Jaffe, E.K., Morpheeins-a new structural paradigm for allosteric regulation. Trends Biochem Sci, 2005, 30, (9), 490-497.
14. Selwood, T.; Jaffe, E.K., Dynamic dissociating homo-oligomers and the control of protein function. Arch Biochem, 2012, 519, (2), 131-143.
15. Lawrence, S.H.; Selwood, T.; Jaffe, E.K., Diverse clinical compounds alter the quaternary structure and inhibit the activity of an essential enzyme. ChemMedChem, 2011, 6, (6), 1067-1073.
16. Ramirez, U.D.; Myachina, F.; Stith, L.; Jaffe, E.K., Docking to Large Allosteric Binding Sites on Protein Surfaces. Adv Exp Med Biol, 2010, 680, 481-488.
17. Lawrence, S.H.; Ramirez, U.D.; Selwood, T.; Stith, L.; Jaffe, E.K., Allosteric inhibition of human porphobilinogen synthase. J Biol Chem, 2009, 284, (51), 35807-35817.
18. Lawrence, S.H.; Ramirez, U.D.; Tang, L.; Fazliyez, F.; Kundrat, L.; Markham, G.D.; Jaffe, E.K., Shape shifting leads to smallmolecule allosteric drug discovery. Chem Biol, 2008, 15, (6), 586-596.
19. Xia, M.; Huang, R.; Witt, K.L.; Southall, N.; Fostel, J.; Cho, M.H.; Jadhav, A.; Smith, C.S.; Inglese, J.; Portier, C.J.; Tice, R.R.; Austin, C.P., Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect, 2008, 116, (3), 284-291.
20. Rasband, W.S. ImageJ, U.S. National Institutes of Health: Bethesda, 1997-2009.
21. Tang, L.; Stith, L.; Jaffe, E.K., Substrate-induced interconversion of protein quaternary structure isoforms. J Biol Chem, 2005, 280, (16), 15786-15793.
22. Jaffe, E.K.; Lawrence, S.H., Allostery and the dynamic oligomerization of porphobilinogen synthase. Arch Biochem Biophys, 2012, 519, (2), 144-153.
23. Wright, J.M.; Schwartz, J.; Vartiainen, T.; Maki-Paakkanen, J.; Altshul, L.; Harrington, J.J.; Dockery, D.W., 3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) and mutagenic activity in Massachusetts drinking water. Environ Health Perspect, 2002, 110, (2), 157-164.
24. Onstad, G.D.; Weinberg, H.S.; Krasner, S.W., Occurrence of halogenated furanones in U.S. drinking waters. Environ Sci Technol, 2008, 42, (9), 3341-3348.
25. Meier, J.R.; Knohl, R.B.; Coleman, W.E.; Ringhand, H.P.; Munch, J.W.; Kaylor, W.H.; Streicher, R.P.; Kopfler, F.C., Studies on the potent bacterial mutagen, 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone: aqueous stability, XAD recovery and analytical determination in drinking water and in chlorinated humic acid solutions. Mutat Res, 1987, 189, (4), 363-373.
26. Le Curieux, F.; Nesslany, F.; Munter, T.; Kronberg, L.; Marzin, D., Genotoxic activity of chlorohydroxyfuranones in the microscale micronucleus test on mouse lymphoma cells and the unscheduled DNA synthesis assay in rat hepatocytes. Mutagenesis, 1999, 14, (5), 457-462.
27. Komulainen, H.; Kosma, V.M.; Vaittinen, S.L.; Vartiainen, T.; Kaliste-Korhonen, E.; Lotjonen, S.; Tuominen, R.K.; Tuomisto, J., Carcinogenicity of the drinking water mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone in the rat. J Natl Cancer Inst, 1997, 89, (12), 848-856.
28. McGovern, S.L.; Helfand, B.T.; Feng, B.; Shoichet, B.K., A specific mechanism of nonspecific inhibition. J Med Chem, 2003, 46, (20), 4265-4272.
29. Van Koten-Vermeulen, J.; Wouters, M.F.A.; Van Leeuwen, F.X.R. Report of the 40th meeting of the joint FAO/WHO expert committee on Food Additives; World Health Organisation: Geneva, 1993; pp 85-123.
30. Kennedy, D.G.; Young, P.B.; McCracken, R.J. In 115th Annual conference of the Swiss Society of Food and Environmental Chemistry; Bundesamt fuer Gesundheit: Berne, 2003; Vol. 94, pp 510-526.
31. Cooper, K.M.; Le, J.; Kane, C.; Kennedy, D.G., Kinetics of semicarbazide and nitrofurazone in chicken eggs and egg powders. Food Addit Contam Part A Chem Anal Control Expo Risk Assess, 2008, 25, (6), 684-692.
32. Gebara, A.B.; Ciscato, C.H.P.; Monteiro, S.H.; Souza, G.S., Pesticide Residues in some Commodities: Dietary Risk for Children. Bull Environ Contam Toxicol, 2011, 86, (5), 506-510.
33. Ludwicki, J.K.; Strucinski, P., Captan. Documentation of proposed values of permissible occupational exposure levels. Podstawy i Metody Oceny Srodowiska Pracy, 2001, 17, (3), 137-156.
34. Nazir, A.; Mukhopadhyay, I.; Saxena, D.K.; Siddiqui, M.S.; Chowdhuri, D.K., Evaluation of toxic potential of captan: Induction of hsp70 and tissue damage in transgenic Drosophila melanogaster (hsp70-lacZ) Bg9. J Biochem Mol Toxicol, 2003, 17, (2), 98-107.
35. Cohen, S.M.; Gordon, E.B.; Singh, P.; Arce, G.T.; Nyska, A., Carcinogenic mode of action of folpet in mice and evaluation of its relevance to humans. Crit Rev Toxicol, 2010, 40, (6), 531-545.
36. Pethran, A.; Schierl, R.; Hauff, K.; Grimm, C.H.; Boos, K.S.; Nowak, D., Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occ Env Hea, 2003, 76, (1), 5-10.
37. Schwarzbauer, J.; Ricking, M.; Franke, S.; Francke, W., Halogenated organic contaminants in sediments of the Havel and Spree rivers (Germany). Part 5 of organic compounds as contaminants of the Elbe river and its tributaries. Environ Sci Technol, 2001, 35, (20), 4015-4025.
38. Brancaccio, R.R.; Cockerell, C.J.; Belsito, D.; Ostreicher, R., Allergic contact dermatitis from color film developers: clinical and histologic features. J Am Acad Dermatol, 1993, 28, (5 Pt 2), 827-830.
39. Hall, L.W.; Overman, J.D.W. Use of organic halogen compounds to reduce or prevent for in negative-working silver halide emulsion. Euorpean Patent Office G03001-34. 1982 Feb.
40. NIEHS, Diglycidyl resorcinol ether. Rep Carcinog, 2011, (12), 163-164.
41. Murthy, A.S.; McConnell, E.E.; Huff, J.E.; Russfield, A.B.; Good, A.E., Forestomach neoplasms in Fischer F344/N rats and B6C3F1 mice exposed to diglycidyl resorcinol ether--an epoxy resin. Food Chem Toxicol, 1990, 28, (10), 723-729.
42. Eastman Chemical Company, US EPA High Production Volume Challenge: Test plan for methyl 4-formylbenzoate. Merrifield, VA, 2003.
43. Godt, J.; Scheidig, F.; Grosse-Siestrup, C.; Esche, V.; Brandenburg, P.; Reich, A.; Groneberg, D.A., The toxicity of cadmium and resulting hazards for human health. J Occup Med Toxicol, 2006, 1, 22.
44. Prozialeck, W.C.; Edwards, J.R., Early biomarkers of cadmium exposure and nephrotoxicity. Biometals, 2010, 23, (5), 793-809.
45. Moulis, J.M., Cellular mechanisms of cadmium toxicity related to the homeostasis of essential metals. Biometals, 2010, 23, (5), 877-896.
46. Chauhan, S.; Titus, D.E.; O'Brian, M.R., Metals control activity and expression of the heme biosynthesis enzyme deltaaminolevulinic acid dehydratase in Bradyrhizobium japonicum. J Bacteriol, 1997, 179, (17), 5516-5520.
47. Mitchell, R.A.; Drake, J.E.; Wittlin, L.A.; Rejent, T.A., Erythrocyte porphobilinogen synthase (delta-aminolaevulinate dehydratase) activity: a reliable and quantitative indicator of lead exposure in humans. Clin Chem, 1977, 23, (1), 105-111.
48. Houghton, P.J., The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol, 1999, 51, (5), 505-512.
49. Khom, S.; Baburin, I.; Timin, E.; Hohaus, A.; Trauner, G.; Kopp, B.; Hering, S., Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology, 2007, 53, (1), 178-187.
50. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 2001, 46, (1-3), 3-26.
51. Jaffe, E.K.; Shanmugan, D.; Gardberg, A.; Dieterich, S.; Sankaran, B.; Stewart, L.J.; Myler, P.J.; Roos, D.S., Crystal structure of Toxoplasma gondii porphobilinogen synthase: insights on octameric structure and porphobilinogen formation. J Biol Chem, 2011,286, (17), 15298-15307.
52. Shanmugam, D.; Wu, B.; Ramirez, U.; Jaffe, E.K.; Roos, D.S., Plastid-associated Porphobilinogen Synthase from Toxoplasma gondii-Kinetic and structural properties validate therapeutic potential. J Biol Chem, 2010, 285, (29), 22122-22131.
53. Kokona, B.; Rigotti, D.J.; Wasson, A.S.; Lawrence, S.H.; Jaffe, E.K.; Fairman, R., Probing the oligomeric assemblies of pea porphobilinogen synthase by analytical ultracentrifugation. Biochemistry, 2008, 47, (40), 10649-10656.
54. Jaffe, E.K., Morpheeins, a new pathway for allosteric drug discovery. The Open Conference Proceedings Journal, 2010, 1, 1-6.